Sino Biological Symposium

Next-Gen Antibody Discovery and Engineering: Advancing Immuno-oncology and Drug Discovery

PROGRAM SCHEDULE

Welcome Note	9:30a.m. - 9:45 a.m.
Dr. Jing Gong **Sino Biological** Accerlerating Drug Discovery and Immunotherapy Research with Cutting-edge Protein Production and Antibody Development Platforms	9:45 a.m. - 10:30 a.m.
Dr. Xavier LEROY **GIO Therapeutics** A New Era in Biomedicine: Antibodies Against GPCRs and Their Therapeutic Application	10:30 a.m. - 11:15 a.m.
Lunch and Networking	11:30 a.m. - 13:00 a.m.
Prof. Dr. Lukas Jeker **Univeristy Hospital of Basel** Molecular Cell Shielding - A Therapeutic Platform Approach for Hematologic Diseases	13:00 a.m. - 13:45 p.m.
Dr. Christian Stocker **Univeristy Hospital of Basel** ANV600 is a novel PD-1 targeted IL-2Rβ/γ agonist that is combinable with therapeutic PD-1 inhibitors	13:45 p.m. - 14:30 p.m.
Dr. Chennakesava CUDDAPAH **Curio Biotech** Significance of primary human in vitro systems in drug discovery	14:30 p.m. - 15:15 p.m.
Dr. Muriel Revol **LubioScience** Introduction to LubioScience, the Reagent Platform in Switzerland.	15:15 p.m. - 15:30 p.m.
Networking Apéro and Closing Remark	

SPEAKERS

Dr. Jing Gong
Technical Specialist at Sino Biological

As a technical specialist at Sino Biological Europe GmbH, Dr. Jing Gong provides technical assistance for their recombinant protein and antibody products, as well as support CRO services of recombinant protein production and antibody development for their customers. Before joining Sino, Dr. Gong obtained his PhD degree in the neurodegenerative disease research field in 2019, in Germany.

Dr. Xavier LEROY
CEO/Founder of GIO Therapeutics

With over 20 years of experience in the biopharma industry, Dr. Xavier LEROY is a biotech leader and entrepreneur who is passionate about bringing innovations that change our outlook on life. He has a Ph.D. in Biology and Pharmacology and an Executive MBA from HEC Paris. Currently, Xavier Leroy is the co-founder and CEO of GIO Therapeutics, a biotech focussed on GPCRs, and an Executive in Residence at Cumulus Oncology, where he collaborates to launch and accelerate the translation of scientific discoveries into breakthrough, high-value medicines that address critical areas of unmet need for patients.

He is also the Founder and President of « Jean & Marie-Claire Leroy » Biodiversity Heritage Site, a non-profit organization that preserves ancestral and historical species and fruit tree's genetic resources. Throughout his career, he has successfully created and enabled new concepts and innovative medicines, brought NCEs and NBEs from research to clinical development, attracted and recruited new teams, and raised funds from investors and government grants. Dr. Xavier Leroy also contributed to several scientific publications and patents in the field of immuno-oncology and oncology.

Dr. Christian Stocker
Scientist Protein Engineering at Anaveon

Christian joined Anaveon in March 2022 after his PhD in biochemistry at ETH Zurich. During his doctoral studies, he performed in-depth characterization of novel exported bifunctional fusion enzymes and in vivo selections of cyclic peptide libraries for protein-protein interaction inhibition by directed evolution. Before that, Christian worked in the Protein Engineering Group at ESBATech, a Novartis Company, where he was responsible for the affinity maturation of scFv antibodies using phage display and the generation of bi-valent and bi-specific variants.

Prof. Dr. Lukas Jeker

Assistant Professor for Experimental Transplantation Immunology and Nephrology at the Basel University Hospital and the Department of Biomedicine of the University of Basel

Lukas has been engaged with projects concerning the engineering of epitopes since 2016. He was born in Roma (Lesotho) in 1975, studied medicine at the Universities of Basel and of Paris, and worked as a resident in Internal Medicine in Davos and Liestal and shortly in Transplantation Immunology and Nephrology in Basel.

In 2005, Professor Jeker graduated from the Swiss MD-PhD program. After research stays in various places, including Baltimore, he worked at the University of California, San Francisco, first as a postdoc doing basic research (2007-2010), then as an Assistant Adjunct Professor (2010 – 2013). In 2014, he returned to Basel, sponsored by a Professorship of the Swiss National Science Foundation, and habilitated in 2016 in Experimental Medicine. In 2020 he co-founded Cimeio Therapeutics AG.

Prof. Jeker investigates the immune system at the cellular and molecular level. His group recently developed “cell shielding” as a versatile platform to address major limitations of hematopoietic stem cell transplantation. His long-term goals include translation of basic insight to the clinics including transplantation immunology.

He is married and the father of two children.

Dr. Chennakesava CUDDAPAH

CEO/Founder of Curio Biotech Ltd

After serving as a research assistant at the Indian Institute of Science, focusing on identifying male contraceptive targets in non-human primates, Chennakava pursued his Ph.D. at the Department for Biomedical Research, University of Bern in Switzerland. Following this, he embarked on a postdoctoral fellowship at the Department of Biomedicine, University of Basel, delving into the mechanisms of antigen processing and presentation in human endothelial cells and their recognition by CD8 T cells.

From 2007 to 2009, Chennakava delved into the immunogenetics of microchimerism in scleroderma and autologous stem cell transplantation as a Research Associate at Fred Hutchinson Cancer Center in the USA. Following this, he continued his research on autoantigens, antibodies, and cell-free DNA in rheumatoid arthritis at the Rheumaklinik, Aarau Hospital, from 2010 to 2011.

Transitioning into management, he served as Manager for Contract Research at Cellntec Advanced Cell Systems in Switzerland from 2011 to 2016, before founding Curio Biotech Ltd. in January 2017, where he currently serves as CEO and Founder.